{"id":15781,"date":"2019-10-28T13:47:46","date_gmt":"2019-10-28T12:47:46","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=15781"},"modified":"2019-10-29T13:51:17","modified_gmt":"2019-10-29T12:51:17","slug":"cato-research-and-sms-oncology-merge","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/","title":{"rendered":"Cato Research and SMS-oncology merge"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><a rel=\"noreferrer noopener\" href=\"http:\/\/www.cato.com\/\" target=\"_blank\">Cato Research<\/a> has merged with\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/sms-oncology.com\/\" target=\"_blank\">Specialized Medical Services-oncology BV<\/a>\u00a0(SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. Headquartered in Schiphol, the Netherlands, SMS-oncology is one of the few full-service contract research organizations (CROs) in the world dedicated to oncology.&nbsp; The boutique CRO\u2019s deep expertise in designing and executing complex oncology and immuno-oncology trials complements CATO\u2019s regulatory knowledge and drug development services.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cCATO and SMS-oncology bring a powerful blend of capabilities focused on supporting small and mid-sized biotech and pharmaceutical companies with their innovative research.&nbsp; Our companies share strong cultural values, anchored by a commitment to high quality and personalized customer service.&nbsp; Together, we\u2019re focused on growing and enhancing our services to build an industry-leading company specializing in complex therapeutic areas, including oncology, cell and gene therapy, and rare treatments,\u201d said Mark A. Goldberg, M.D., executive chairman, CATO.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Philine van den Tol, CEO, SMS-oncology, added, \u201cComing together with CATO is an important step toward our objective of providing clients with a broader set of solutions supported by the high-touch service that they expect from us.&nbsp; We can now offer our clients an expanded geographic footprint in the United States and Canada, as well as additional access to valuable drug development and regulatory expertise.&nbsp; We\u2019re especially excited to engage CATO\u2019s expertise in working with the FDA.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ms. Van den Tol and the management team will continue to lead the company\u2019s operations. Dr. Goldberg will serve as executive chairman of the combined entity.&nbsp; CATO and SMS-oncology will operate under their respective brands until the transition to their new name, CATO SMS, is complete.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CATO\u2019s merger with SMS-oncology is the latest step in the company\u2019s strategic expansion since Water Street Healthcare Partners and JLL Partners invested in the company last year. The health care investors recently announced the acquisition of THREAD, a provider of innovative technology that enables virtual research.&nbsp; CATO can engage THREAD on opportunities where clients want to leverage its platform to modernize their clinical studies and registries through technology-enabled interactions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <a href=\"https:\/\/sms-oncology.com\/news\/press-releases\/cato-research-announces-merger-with-sms-oncology\/\"><strong>SMS-oncology<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cato Research has merged with\u00a0Specialized Medical Services-oncology BV\u00a0(SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year. By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-15781","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cato Research and SMS-oncology merge - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cato Research and SMS-oncology merge - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Cato Research has merged with\u00a0Specialized Medical Services-oncology BV\u00a0(SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year. By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-28T12:47:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-10-29T12:51:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Cato Research and SMS-oncology merge\",\"datePublished\":\"2019-10-28T12:47:46+00:00\",\"dateModified\":\"2019-10-29T12:51:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/\"},\"wordCount\":405,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/\",\"name\":\"Cato Research and SMS-oncology merge - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-10-28T12:47:46+00:00\",\"dateModified\":\"2019-10-29T12:51:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cato-research-and-sms-oncology-merge\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cato Research and SMS-oncology merge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cato Research and SMS-oncology merge - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/","og_locale":"en_US","og_type":"article","og_title":"Cato Research and SMS-oncology merge - hollandbio","og_description":"Cato Research has merged with\u00a0Specialized Medical Services-oncology BV\u00a0(SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year. By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/","og_site_name":"hollandbio","article_published_time":"2019-10-28T12:47:46+00:00","article_modified_time":"2019-10-29T12:51:17+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Cato Research and SMS-oncology merge","datePublished":"2019-10-28T12:47:46+00:00","dateModified":"2019-10-29T12:51:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/"},"wordCount":405,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/","name":"Cato Research and SMS-oncology merge - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-10-28T12:47:46+00:00","dateModified":"2019-10-29T12:51:17+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cato-research-and-sms-oncology-merge\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Cato Research and SMS-oncology merge"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=15781"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/15781\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=15781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=15781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=15781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}